<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00461825</url>
  </required_header>
  <id_info>
    <org_study_id>Afssaps-980654</org_study_id>
    <nct_id>NCT00461825</nct_id>
  </id_info>
  <brief_title>Maintenance Neoral Monotherapy Compared to Bitherapy in Renal Transplantation</brief_title>
  <official_title>Efficacy and Safety of Maintenance Neoral Compared to Bitherapy Neoral-Imurel or Neoral-CellCept in Renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We have previously defined factors that predict the long term success of maintenance CsA
      monotherapy (CsAm) after kidney transplantation : donor age &lt; 40 years, serum creatinine
      level at the initiation of CsAm £ 125 µmol/L, no rejection episode before CsAm initiation. We
      have also shown that the 8-year graft survival in 329 selected patients enrolled in
      maintenance CsA-m was 84 % (Hurault de Ligny et al, Transplantation, 2000 ; 69 : 1327-1332).
      These results were obtained with an old formulation of cyclosporin, azathioprine, steroid
      withdrawal over the first year and induction antibody. This prospective randomized
      multicentre study was designed to clarify whether maintenance Neoral + MMF or Neoral + AZA is
      better than a CsAm and wether Neoral + MMF is better than Neoral + AZA in low immunological
      risk cadaveric kidney transplant recipients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Between july 1998 and january 2004 selected patients were randomly assigned equally within
      each centre to receive CsAm or bitherapy with equally CsA + MMF or CsA + AZA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1998</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to compare maintenance CsAm with dual therapy groups and within dual therapy MMF with AZA for :</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence and the delay of occurrence of graft dysfunction episode defined as ³ 20 % increase in serum creatinine level (mean of three results obtained in the same laboratory) and requiring a graft biopsy.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Causes of graft dysfunction episodes diagnosed by graft biopsy.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of serious infections (HVZ, EBV, HPV genital infection, febrile UTI, pneumonitis...)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the three treatment groups for the following parameters :</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of therapeutic failure defined by biopsy proven acute rejection episode or CsA renal toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft function evaluated by serum creatinine level and calculated creatinine clearance (CG formula)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and graft survival</measure>
  </secondary_outcome>
  <enrollment>207</enrollment>
  <condition>Kidney Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporin A: C0: 75–125ng/ml-dose adapted in the 3 groups</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group A: CsA + Azathioprine(1 to 2 mg/kg/day)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group B: CsA + CellCept(500 mg x 2/day)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group C: CsAm</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion criteria:

               -  Primary cadaveric renal transplant with induction therapy, delayed Neoral, MMF
                  and prednisone

               -  Steroid withdrawal &gt;= 3 months before enrolment

               -  Bitherapy Neoral + CellCept

               -  Follow up time since transplantation : 11-24 months

               -  Recipient age &gt;= 25 years

               -  Donor age &lt;= 45 years

               -  Serum creatinine level &lt;= 125 µmol/L and/or calculated creatinine clearance &gt;= 50
                  ml/mn (CG formula)

               -  No or only one steroid-sensitive acute rejection episode during the first year
                  post-transplantation

               -  PRA &lt;= 25 %

               -  Written informed consent

          -  Exclusion Criteria:

               -  Living donor transplantation

               -  Recipient receiving tacrolimus

               -  Azathioprine intolerance

               -  Thrombopenia &lt; 100 000/mm³

               -  Neutropenia &lt; 1500/mm³

               -  Hemoglobinemia &lt;= 8g/dl

               -  On going infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TOUCHARD Guy, MD,Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poitiers University Hospital, POITIERS, 86021, FRANCE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Caen university Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dupuytren University Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poitiers University hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reims University Hospital</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Hurault de Ligny B, Toupance O, Lavaud S, Bauwens M, Peyronnet P, Le Meur Y, Ryckelynck JP, Jolly D, Leroux-Robert C, Touchard G. Factors predicting the long-term success of maintenance cyclosporine monotherapy after kidney transplantation. Transplantation. 2000 Apr 15;69(7):1327-32.</citation>
    <PMID>10798748</PMID>
  </reference>
  <reference>
    <citation>Touchard G, Hauet T, Cogny Van Weydevelt F, Hurault de Ligny B, Peyronnet P, Lebranchu Y, Toupance O, N'Doye P, Busson M. Maintenance cyclosporin monotherapy after renal transplantation--clinical predictors of long-term outcome. Nephrol Dial Transplant. 1997 Sep;12(9):1956-60.</citation>
    <PMID>9306349</PMID>
  </reference>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2007</study_first_submitted>
  <study_first_submitted_qc>April 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2007</study_first_posted>
  <last_update_submitted>April 17, 2007</last_update_submitted>
  <last_update_submitted_qc>April 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2007</last_update_posted>
  <keyword>Immunosuppression</keyword>
  <keyword>Kidney transplantation</keyword>
  <keyword>multicenter study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

